Name | 2'-deoxy-2'-fluoro-2'-C-methyluridine |
Synonyms | RO 2433 PSI-6206 2'-Deoxy-2-floro-2'Methyl-uridine 2'-deoxy-2'-fluoro-2'-C-methyluridine 2'-Deoxy-2'-Fluoro-2'-C-Methyl Uridine (2'R)-2'-Deoxy-2'-fluoro-2'-methyluridine (2'R)-2'-deoxy-2'-fluoro-2'-methyl-Uridine Uridine, 2'-deoxy-2'-fluoro-2'-Methyl-, (2'R)- Uridine, 2'-deoxy-2'-fluoro-2'-Methyl-, (2'R)- PSI6206 1-((2S,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxyMethyl)-3-Methyltetrahydrofuran-2-yl)pyriMidine-2,4(1H,3H)-dione 1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione 1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxyMethyl)-3-Methyltetrahydrofuran-2-yl)pyriMidine-2,4(1H,3H)-dione |
CAS | 863329-66-2 |
EINECS | 810-481-6 |
Molecular Formula | C10H13FN2O5 |
Molar Mass | 260.22 |
Density | 1.55 |
Melting Point | 237-238℃ |
Solubility | DMSO (Slightly), Methanol (Slightly, Heated) |
Appearance | Solid |
Color | White to Light Beige |
pKa | 9.39±0.10(Predicted) |
Storage Condition | Sealed in dry,Store in freezer, under -20°C |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.843 ml | 19.215 ml | 38.429 ml |
5 mM | 0.769 ml | 3.843 ml | 7.686 ml |
10 mM | 0.384 ml | 1.921 ml | 3.843 ml |
5 mM | 0.077 ml | 0.384 ml | 0.769 ml |
apply | (2'R)-2 '-deoxy -2'-fluoro -2 '-methyluridine is a key pharmaceutical intermediate, sofosbuvir(CAS:1190307-88-0) key pharmaceutical intermediate, it has important application significance and economic value. On 17. This approval of Sovaldi, a once-daily oral nucleoside analog polymerase inhibitor, paves the way for the drug to be marketed throughout the European Union. Previously, Sovaldi received a positive opinion recommended for approval by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in November 2013. In the United States, Sovaldi was approved by the FDA in December 2013. It is the first drug approved for the full oral treatment of hepatitis C, the need for the traditional injectable drug interferon (IFN) can be eliminated. Chronic hepatitis C (HCV) is the leading cause of liver cancer and liver transplantation in Europe and around the world. |
biological activity | PSI-6206 (RO-2433, GS-331007) is a potent inhibitor of HCV RNA-dependent RNA polymerase, targeting NS5B polymerase. |
Use | sofosbuvir/1190307-88-0 intermediate |